Patients on multiple daily injections (MDI) insulin therapy and Dexcom CGM saw greater A1C reduction than those on pump therapy and self-monitoring of blood glucose (SMBG).1
Medicare now provides coverage for therapeutic CGM systems (those approved for use in making diabetes treatment decisions). The Dexcom G5® Mobile CGM System is the first and only mobile-enabled CGM system covered as a Medicare benefit.
CMS approves coverage for Dexcom G6 CGM, the only CGM system recognized by Medicare that offers mobile device compatibility and no fingerstick calibration
Soupal J, Petruzelkova L, Flekac M, et al. Comparison of Different Treatment Modalities for Type 1 Diabetes, Including Sensor-Augmented Insulin Regimens, in 52 Weeks of Follow-Up: A COMISAIR Study. Diabetes Technol Ther. 2016;18(9):532-538.
Beck RW, Riddlesworth T, Ruedy K, et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial. JAMA. 2017;317(4):371-378.